VINCOV-19, an antidote, and a cure against COVID-19, successfully completes Phase 2 Clinical Trials Kumar Jeetendra | October 13, 2022 VINS Bioproducts Limited, a leading immunological company, based in Hyderabad, in collaboration with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), announced the successful completion of Phase 2 Clinical Trials of VINCOV-19, India’s first antidote and a cure against SARS-CoV-2 virus. VINCOV-19 is now ready for market authorization and …
Cipla’s Indore plant joins the World Economic Forum’s (WEF) prestigious Lighthouse Network Kumar Jeetendra | October 11, 2022 Cipla Limited (BSE: 500087; NSE: CIPLA EQ) (“Cipla”) today announced that its Indore Oral Solid Dosage (OSD) plant has been designated by the World Economic Forum as an ‘Advanced Fourth Industrial Revolution (4IR) Lighthouse’. This is the first Cipla facility to receive the coveted recognition. The organisation is amongst the first pharmaceutical companies in India …
‘Listen to the Future’- Cipla’s digital film reinforces its ESG commitments Kumar Jeetendra | September 14, 2022 Mumbai, India, 14th September: Cipla Limited launched a thought-provoking brand film ‘Listen to the Future’ to reiterate the company’s ESG goals for 2030. To bring alive its ethos of contributing toward a greener environment and sustainable value creation, the film creatively highlights the importance of positive actions through the lens of children. The brand film …
Cipla Health’s “Naselin Shubhratri, Prajapati – The Guard” campaign bags “Silver” at Effie APAC Awards 2022 Kumar Jeetendra | September 9, 2022 Mumbai, 9 September: Naselin, one of the leading nasal decongestant brands by Cipla Health has swayed the stage away by winning the “Silver” at the Effie APAC Awards for its captivating yet appealing “Naselin Shubhratri, Prajapati – The Guard” campaign. Naselin becomes Cipla’s first ever brand to win a marketing award in the Asian Pacific region, which is one of the industry’s …
Cipla receives USFDA approval for generic version of Revlimid® (lenalidomide capsules) Kumar Jeetendra | September 7, 2022 Mumbai, India/ New Jersey, United States, September 7, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) (“Cipla”) announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the United States Food and Drug Administration (US FDA). Cipla’s Lenalidomide …
Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets USP, 25 mg and 50 mg. Kumar Jeetendra | August 29, 2022 29th August 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Chlorthalidone Tablets USP, 25 mg and 50 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Hygroton Tablets, …
Pfizer ranked as leading company in Asia for covid-19 response and patient-centric approach by Asian patient groups Kumar Jeetendra | August 26, 2022 SINGAPORE, 26 AUGUST 2022 — Pfizer had been ranked first in its Covid-19 response, patient centricity, patient safety and bringing innovative, high-quality products amongst pharma companies in Asia in the ‘Corporate Reputation of Pharma’ survey by patient groups across the APAC region. Overall, the company is ranked second for its corporate reputation across Asian countries. …
Aleor Dermaceuticals Limited receives USFDA Final Approval for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%. Kumar Jeetendra | August 8, 2022 Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) …
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Diclofenac Sodium Topical Gel, 3%. Kumar Jeetendra | August 1, 2022 Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 3%.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Solaraze Topical Gel, …
Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru Kumar Jeetendra | July 7, 2022 Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), has received a EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022. The facility, spread across 340,000-square feet, …
Cipla signs agreement for acquisition of 21.05% stake in Achira Labs to develop affordable, innovative medical kits in India Kumar Jeetendra | June 17, 2022 Mumbai, India; June 17, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has signed definitive agreements for acquisition of 21.05% stake (on a fully diluted basis) for an amount of INR 25 crores (approx.) in Achira Labs Private Limited (hereafter referred to as “Achira”) engaged …
Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa Kumar Jeetendra | June 14, 2022 CAPE TOWN/MUMBAI, 14th June 2022 – The South African Health Products Regulatory Authority (SAHPRA) has approved a sweet-tasting, heat-stable, ‘4-in-1’ fixed-dose combination of four antiretroviral (ARV) treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV. This combination treatment has been developed by Cipla Limited (BSE: …
